New Chronix Liquid Biopsy Test Could Save Doctors On Immunotherapy Costs

Chronix Biomedical continues to demonstrate the potential of its blood-based cancer test across a growing range of indications – this time, its ability to help doctors assess how well patients are responding to immunotherapy, at an earlier stage than current diagnostic imaging methods.

Chronix Biomedical Inc. will start offering around a month from now its circulating cell-free tumour DNA-based test to monitor patients undergoing immunotherapy, following positive results from a study demonstrating the test's ability to predict therapeutic response to immunotherapy in multiple solid tumor types. Results from the study were published in the journal Clinical Cancer Research on Mar 20.

The liquid biopsy test uses proprietary algorithms to derive a copy number instability (CNI) score from sequencing circulating cell-free tumour DNA (cfDNA). Unlike conventional cancer molecular diagnostics, which seek to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Oncology

More from Device Area